Sionna Therapeutics, Inc. Common Stock (NASDAQ:SION) — Market Cap & Net Worth
Market Cap & Net Worth: Sionna Therapeutics, Inc. Common Stock (SION)
Sionna Therapeutics, Inc. Common Stock (NASDAQ:SION) has a market capitalization of $1.66 Billion ($1.66 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6946 globally and #2028 in its home market, demonstrating a 2.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sionna Therapeutics, Inc. Common Stock's stock price $39.15 by its total outstanding shares 44998073 (45.00 Million). Analyse Sionna Therapeutics, Inc. Common Stock operating cash flow efficiency to see how efficiently the company converts income to cash.
Sionna Therapeutics, Inc. Common Stock Market Cap History: 2025 to 2026
Sionna Therapeutics, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $1.85 Billion to $1.76 Billion (0.00% CAGR).
Index Memberships
Sionna Therapeutics, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.07% | #182 of 976 |
Weight: Sionna Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sionna Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sionna Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SION by Market Capitalization
Companies near Sionna Therapeutics, Inc. Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Sionna Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Sionna Therapeutics, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Sionna Therapeutics, Inc. Common Stock's market cap moved from $1.85 Billion to $ 1.76 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.76 Billion | -4.84% |
| 2025 | $1.85 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Sionna Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.66 Billion USD |
| MoneyControl | $1.66 Billion USD |
| MarketWatch | $1.66 Billion USD |
| marketcap.company | $1.66 Billion USD |
| Reuters | $1.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more